Chinese drug makers landed 33 licensing deals with overseas pharmaceutical firms, with transactions totalling US$36.2 billion ...

Judging by the present cost of production at the clinical research stage, Cheng, who previously worked as a biological ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

ImmuneOnco Biopharmaceuticals has shown Chinese biotechs are far from immune to the pressures to prioritize pipelines. | ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% ...

By Mariam Sunny (Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories ...

Last week, Lilly's newly-opened Lilly Gateway Labs in Beijing welcomed its first tenant, namely a Chinese biotechnology company focusing on innovative medicines for neurodegenerative and neurological ...

The severe ESG risk rating is consistent with Chinese biotech company ratings on Sustainalytics. The risks are primarily from product governance and regulatory uncertainties. We assign Innovent an ...

Investing.com -- The latest tariffs imposed by the Trump administration are not a major concern for the China healthcare ...

The total deal value of US licensing of innovator drug candidates from Chinese biopharma companies has surged 280% since 2020.

(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

Julie Gilmore, vice-president and global head of LGL & Catalyze360 Portfolio Management, said, "Our expansion in Beijing will enable leading Chinese biotech enterprises to access unparalleled ...